Polyphor Ltd and Axxam SpA Announce Ion Channel Collaboration
Polyphor Ltd and Axxam SpA announced a joint discovery agreement with a synergistic combination of their discovery platforms. Under the terms of the collaboration the two companies will work together to discover and develop innovative drug candidates for selected therapeutic areas such as pain, inflammation, and metabolic disorders. Axxam will apply its expertise and outstanding Hit Discovery platforms and capabilities and Polyphor will provide its unique, proprietary PEM finder® library for screening together with its expertise in medicinal chemistry, drug discovery and development. The collaboration comprises several discovery programs addressing very attractive ion channel based targets.
“We believe that our unique cooperation and the complementary skill sets of both companies will offer a valuable alternative for innovation in the demanding field of ion channel based drugs and will industrialize the process for the generation of novel drugs for high medical needs”, added Stefan Lohmer, Chairman and CEO of Axxam.
Jean-Pierre Obrecht, CEO of Polyphor said: “We have selected Axxam as the preferred partner because of its strong expertise in assay development and HTS, in particular in the field of ion-channels. This capability will allow Polyphor to efficiently exploit the potential of its proprietary drug development platforms and accelerate the identification of novel research programs.”
Other news from the department business & finance
